Source of this article and featured image is Wired Science. Description and key fact are generated by Codevision AI system.
A groundbreaking gene-editing therapy using Crispr has shown promising results in reducing cholesterol levels in a small group of patients. The treatment, developed by Crispr Therapeutics, targets a gene in the liver called ANGPTL3, which is linked to heart disease. The therapy significantly lowered LDL cholesterol and triglycerides by up to 50% within two weeks. The effects were sustained for at least 60 days, marking a significant step forward in the application of gene editing. This development highlights the potential of Crispr to treat common health conditions beyond rare diseases.
Key facts
- A gene-editing therapy using Crispr reduced LDL cholesterol and triglycerides by 50% in a small group of patients.
- The treatment targets the ANGPTL3 gene in the liver, which is associated with heart disease.
- The effects of the therapy lasted at least 60 days, as observed in the trial.
- The findings were presented at the American Heart Association’s annual meeting and published in The New England Journal of Medicine.
- Crispr Therapeutics is behind the only approved gene-editing treatment on the market, Casgevy.
